Literature DB >> 32253502

Luliconazole, a highly effective imidazole, against Fusarium species complexes.

Maral Gharaghani1,2, Sahar Hivary2, Simin Taghipour2,3, Ali Zarei-Mahmoudabadi4,5.   

Abstract

Luliconazole is a new antifungal that was primarily used for the treatment of dermatophytosis. However, some studies have shown that it has excellent efficacy against Aspergillus and Candida species in vitro. The present study aimed to evaluate of luliconazole activity against some Fusarium species complex isolates. In this study, 47 isolates of Fusarium were tested against several antifungals including luliconazole. All species were identified using morphology features, and PCR sequencing and antifungal susceptibility were performed according to CLSIM38 A3 guideline. Our results revealed that luliconazole has a very low minimum inhibitory concentration value (0.0078-1 µg/ml) in comparison with other tested antifungals. Amphotericin B had a poor effect with a high MIC90 (64 µg/ml), followed by terbinafine (32 µg/ml), posaconazole (16 µg/ml), caspofungin (16 µg/ml), voriconazole (4 µg/ml), and itraconazole (4 µg/ml). Overall, our findings indicated that luliconazole has great activity against environmental and clinical Fusarium species complexes in comparison to tested antifungals.

Entities:  

Keywords:  Antifungal susceptibility; Fusarium; Luliconazole

Mesh:

Substances:

Year:  2020        PMID: 32253502     DOI: 10.1007/s00430-020-00672-4

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  2 in total

1.  Eumycetoma causative agents are inhibited in vitro by luliconazole, lanoconazole and ravuconazole.

Authors:  Bertrand Nyuykonge; Wilson Lim; Lukas van Amelsvoort; Alexandro Bonifaz; Ahmed Fahal; Hamid Badali; Mahdi Abastabar; Annelies Verbon; Wendy van de Sande
Journal:  Mycoses       Date:  2022-05-06       Impact factor: 4.931

2.  Development and Optimization of Luliconazole Spanlastics to Augment the Antifungal Activity against Candida albicans.

Authors:  Nabil A Alhakamy; Mohammed W Al-Rabia; Shadab Md; Alaa Sirwi; Selwan Saud Khayat; Sahar Saad AlOtaibi; Raghad Abkar Hakami; Hadeel Al Sadoun; Basmah Medhat Eldakhakhny; Wesam H Abdulaal; Hibah M Aldawsari; Shaimaa M Badr-Eldin; Mahmoud A Elfaky
Journal:  Pharmaceutics       Date:  2021-06-28       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.